The PK Papyrus covered coronary stent system (Biotronik) has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is designed to be used in emergency situations to create a physical barrier to seal perforated coronary arteries without the need for invasive surgery. In September 2018, it became the first FDA-approved device for the treatment of coronary artery perforation in nearly two decades.

Since 1970, the Galien Foundation has recognised and rewarded outstanding achievements in scientific innovation in improving the state of human health. The biomedical and medical technology industries consider this award as one of the highest accolades in the field of biopharmaceutical research. Award winners will be announced during the October 24 Prix Galien USA Awards Ceremony in New York City.

Ryan Walters, president of Biotronik USA, comments: “The Prix Galien nomination for PK Papyrus is a recognition of Biotronik’s ongoing efforts to develop trusted and innovative technology solutions. PK Papyrus marks a long overdue advancement in the field of interventional cardiology and further demonstrates Biotronik’s commitment to innovation and advancement in the field, offering hospital administrators, physicians and their patients the best in technology for many years to come.”

PK Papyrus is 5F and 6F guide catheter compatible, and available in 17 sizes, offering the ability to treat perforations in vessels between 2.5mm and 5mm in diameter.